Cargando…
P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION
| Autores principales: | , , , , , , , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430867/ http://dx.doi.org/10.1097/01.HS9.0000846204.59341.a5 |
| _version_ | 1784779894654238720 |
|---|---|
| author | Röth, A. Egyed, M. Ichikawa, S. Ito, Y. Kim, J. S. Nagy, Z. Obara, N. Panse, J. Schrezenmeier, H. Sica, S. Soret, J. Usuki, K. Yoon, S.-S. Benkali, K. Buri, M. Lundberg, P. Patel, H. Shinomiya, K. Sreckovic, S. Nishimura, J.-I. |
| author_facet | Röth, A. Egyed, M. Ichikawa, S. Ito, Y. Kim, J. S. Nagy, Z. Obara, N. Panse, J. Schrezenmeier, H. Sica, S. Soret, J. Usuki, K. Yoon, S.-S. Benkali, K. Buri, M. Lundberg, P. Patel, H. Shinomiya, K. Sreckovic, S. Nishimura, J.-I. |
| author_sort | Röth, A. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9430867 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94308672022-08-31 P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION Röth, A. Egyed, M. Ichikawa, S. Ito, Y. Kim, J. S. Nagy, Z. Obara, N. Panse, J. Schrezenmeier, H. Sica, S. Soret, J. Usuki, K. Yoon, S.-S. Benkali, K. Buri, M. Lundberg, P. Patel, H. Shinomiya, K. Sreckovic, S. Nishimura, J.-I. Hemasphere Posters Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9430867/ http://dx.doi.org/10.1097/01.HS9.0000846204.59341.a5 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Posters Röth, A. Egyed, M. Ichikawa, S. Ito, Y. Kim, J. S. Nagy, Z. Obara, N. Panse, J. Schrezenmeier, H. Sica, S. Soret, J. Usuki, K. Yoon, S.-S. Benkali, K. Buri, M. Lundberg, P. Patel, H. Shinomiya, K. Sreckovic, S. Nishimura, J.-I. P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_full | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_fullStr | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_full_unstemmed | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_short | P830: CROVALIMAB MAINTAINS CLINICAL BENEFIT OVER LONG-TERM TREATMENT IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA: RESULTS FROM THE COMPOSER TRIAL OPEN-LABEL EXTENSION |
| title_sort | p830: crovalimab maintains clinical benefit over long-term treatment in patients with paroxysmal nocturnal hemoglobinuria: results from the composer trial open-label extension |
| topic | Posters |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9430867/ http://dx.doi.org/10.1097/01.HS9.0000846204.59341.a5 |
| work_keys_str_mv | AT rotha p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT egyedm p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT ichikawas p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT itoy p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT kimjs p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT nagyz p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT obaran p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT pansej p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT schrezenmeierh p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT sicas p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT soretj p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT usukik p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT yoonss p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT benkalik p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT burim p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT lundbergp p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT patelh p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT shinomiyak p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT sreckovics p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension AT nishimuraji p830crovalimabmaintainsclinicalbenefitoverlongtermtreatmentinpatientswithparoxysmalnocturnalhemoglobinuriaresultsfromthecomposertrialopenlabelextension |